key: cord-0720688-l15w31rk
authors: Teixeira, Lívia; Temerozo, Jairo R.; Pereira-Dutra, Filipe S.; Ferreira, André Costa; Mattos, Mayara; Gonçalves, Barbara Simonson; Sacramento, Carolina Q.; Palhinha, Lohanna; Cunha-Fernandes, Tamires; Dias, Suelen S. G.; Soares, Vinicius Cardoso; Barreto, Ester A.; Cesar-Silva, Daniella; Fintelman-Rodrigues, Natalia; Pão, Camila R. R.; de Freitas, Caroline S.; Reis, Patrícia A.; Hottz, Eugenio D.; Bozza, Fernando A.; Bou-Habib, Dumith C.; Saraiva, Elvira M.; de Almeida, Cecília J. G.; Viola, João P. B.; Souza, Thiago Moreno L.; Bozza, Patricia T.
title: Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts
date: 2022-02-18
journal: Front Immunol
DOI: 10.3389/fimmu.2022.820131
sha: b4b34ba898c5ce5fddf74e8d2ea9dc27dda5c656
doc_id: 720688
cord_uid: l15w31rk

Coronavirus disease 2019 (COVID-19) is currently a worldwide emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In observational clinical studies, statins have been identified as beneficial to hospitalized patients with COVID-19. However, experimental evidence of underlying statins protection against SARS-CoV-2 remains elusive. Here we reported for the first-time experimental evidence of the protective effects of simvastatin treatment both in vitro and in vivo. We found that treatment with simvastatin significantly reduced the viral replication and lung damage in vivo, delaying SARS-CoV-2-associated physiopathology and mortality in the K18-hACE2-transgenic mice model. Moreover, simvastatin also downregulated the inflammation triggered by SARS-CoV-2 infection in pulmonary tissue and in human neutrophils, peripheral blood monocytes, and lung epithelial Calu-3 cells in vitro, showing its potential to modulate the inflammatory response both at the site of infection and systemically. Additionally, we also observed that simvastatin affected the course of SARS-CoV-2 infection through displacing ACE2 on cell membrane lipid rafts. In conclusion, our results show that simvastatin exhibits early protective effects on SARS-CoV-2 infection by inhibiting virus cell entry and inflammatory cytokine production, through mechanisms at least in part dependent on lipid rafts disruption.

Coronavirus disease 2019 (COVID- 19) is currently a worldwide emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (1) . Although most individuals with SARS-CoV-2 infection develop only mild respiratory symptoms, during the most severe clinical manifestations of the disease, patients evolve to multiple organs and systems dysfunction, mimicking viral sepsis (2, 3) . The susceptibility to developing severe COVID-19 is determined by various preexisting conditions, such as old age, obesity, diabetes mellitus, and cardiovascular diseases (4, 5) .

Since hypercholesterolemia is often observed in obesity, diabetes mellitus, and cardiovascular diseases, many people at high risk of developing severe COVID-19 use statins regularly to lower their cholesterol levels (6, 7) . Statins are cholesterollowering drugs that inhibit hydroxyl-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in intracellular cholesterol synthesis (8) . Simvastatin also decreases the cholesterol content of lipid rafts, thus displacing various proteins residing in these domains (9) . Notwithstanding, several studies have shown that statins impair hyper inflammation and prevent thromboembolic events (8, 10, 11) , making statins good candidates as adjuvant therapy for COVID-19 (12) (13) (14) . Additionally, the pre-existing statin therapy has been associated with lower mortality and improved clinical parameters in COVID-19 compared to patients without statin therapy (2) . Statin use prior to hospitalization reduces the risk of developing severe COVID-19 and accelerates patients' recovery and hospital discharge (6, 7) . Patients who remained on statins during hospitalization also exhibited a lower mortality rate compared to patients who stopped receiving statins after hospital admission (15) . A recent updated meta-analysis including twenty-five cohorts and 147.824 patients also concluded that the use of statins is associated with a lower risk of mortality in COVID-19 patients (16) .

Despite the great potential of simvastatin as an adjuvant treatment against COVID-19, the mechanisms underlying its suggested protection against SARS-CoV-2 infection are still poorly explored. Here we investigate the effects and mechanisms of statin-pretreatment in SARS-CoV-2 infection and inflammation. Using the COVID K18-hACE2-transgenic mouse model, we demonstrated that simvastatin reduced the viral replication and lung damage in vivo. We also provide evidence that the pleiotropic effects of simvastatin modulate the SARS-CoV-2-induced pro-inflammatory response. Moreover, our data suggest that simvastatin reduced viral replication by mechanisms at least in part dependent on lipid rafts disruption

S i m v a s t a t i n w a s p u r c h a s e d f r o m S i g m a -A l d r i c h (Cat#567020). Reconstitution was performed according to the manufacturer's instructions.

The in vivo studies were conducted according to the guidelines of Committee on the Use of Laboratory Animals of the Oswaldo Cruz Foundation (CEUA-FIOCRUZ) with license L003/21 and to the animal welfare guidelines of the Ethics Committee of Animal Experimentation from National Cancer Institute of Brazil (CEUA-INCA) with license 005/2021. Experimental procedures involving human cells from healthy donors were performed with samples obtained after written informed consent and were approved by the Institutional Review Board (IRB) of the Oswaldo Cruz Institute/Fiocruz (Rio de Janeiro, RJ, Brazil) under the number 49971421.8.0000.5248.

The SARS-CoV-2 D614G (GenBank #MT710714) and Gamma strains (#EPI_ISL_1060902) were originally isolated from nasopharyngeal swabs of a confirmed case from Rio de Janeiro/ Brazil. after a single passage in cell culture, and virus expansion was performed in Vero E6 cells cultured in 150 cm 2 flasks with high glucose DMEM plus 2% fetal bovine serum (FBS; HyClone) at 37°C in 5% CO 2 . Cytopathic effects were monitored daily and peaked 4 to 5 days after infection. According to WHO guidelines, all procedures involving handling infectious virus suspensions were carried out in a biosafety level 3 (BSL3) multiuser facility. Virus titers were determined as 50% of tissue culture infectious dose (TCID50/ mL), and virus stocks were kept in -80°C ultralow freezers.

K18-hACE2-transgenic mice (20-30 g) were obtained from the Oswaldo Cruz Foundation breeding colony. The animals were maintained with free access to food and water and kept at 25-28°C under a controlled 12 h light/dark cycle. Experiments were performed during the light phase of the cycle.

For infection procedures, mice were anesthetized with 60 mg/kg of ketamine and 4 mg/kg of xylazine and inoculated intranasally with medium (Mock), or 10 5 TCID of SARS-CoV-2 gamma strain in 25 µl of the medium. Treated groups received oral doses of 20 mg/kg of simvastatin 24 h and 1 h before infection (pretreatment). The same dose was given once daily for the subsequent days throughout the experiment. According to WHO guidelines, all procedures were performed in an Animal Biosafety Level 3 (ABSL-3) multiuser facility. Animals were monitored daily for eleven days for survival and body-weight analysis. The clinical score was determined by the observation of following signs: piloerection, curved trunk, alterations in gait, seizures, limb paralysis, coma, respiratory rate, skin color alterations, heart rate, lacrimation, palpebral closure, decreased grip strength, limb, abdominal and body tone and body temperature alterations. The clinical evaluation was based on a multifactorial SHIRPA protocol, with the modifications of Reis et al. (17) .

To evaluate the inflammatory process induced by SARS-CoV-2 infection in the lung, mice were euthanized on day 6 after infection and bronchoalveolar lavage (BAL) from both lungs were harvested by washing the respiratory tract with 1 mL of cold PBS. After centrifugation of BAL (1500 rpm for 5 min), the pellets were used for total and differential leukocyte counts (diluted in Turk's 2% acetic acid fluid) using a Neubauer chamber. Lactate dehydrogenase (LDH) activity was evaluated in centrifuged BAL supernatant to evaluate cell death (CytoTox96, Promega, USA). Differential cell counts were performed on cytocentrifuge preparations made using the Cytospin 3 (350 x g for 5 minutes at room temperature) and stained by the May-Grünwald-Giemsa method.

After BAL harvesting, lungs were perfused with 5 ml of PBS to remove the circulating blood and, then, collected, pottered, and homogenized in 750 µL of PBS containing the complete EDTAfree protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany) for 30 sec, using an Ultra-Turrax Disperser T-10 basic IKA (Guangzhou, China). Homogenates were stored at −20°C for cytokine and chemokine measurements.

Myeloperoxidase activity was assayed spectrophotometrically using the method of Bradley et al. (18) . Briefly, lung tissue sample was homogenized in 0.5% hexadecyltrimethylammonium bromide (HTAB -Sigma Chemical Co, St Louis, MO) in 50 mmol/L potassium phosphate buffer, pH 6.0. For each 50 mg of tissue, 100 mL of HTAB buffer was used. Suspensions were then centrifuged at 40,000g for 30 minutes and the resulting supernatant further assayed. Next, in 96-well plates, 50 mL of the supernatant was added together with 50 mL of HTAB plus 50 mL of orthodianisidine (0.167 mg/mL; Sigma Chemical) for 30 min at 37°C, and then 50 mL of H 2 O 2 (0.0005%, Sigma Chemical) was added to each well. After 10 min, the samples underwent analysis in a spectrophotometer (460 nm), and the result was adjusted by tissue mg.

Histological features related to the injury caused by SARS-CoV-2 infection were analyzed in the lungs of K18-hACE2 mice. Inflammatory and vascular infiltrates and evidence of cell degeneration was evaluated to characterize the level of the tissue damage. The collected material was fixed with formaldehyde (4%), dehydrated and embedded in paraffin to the obtention of tissue slices using a microtome. The slices were stained with hematoxylin and eosin and scanned for analysis using the Pannoramic Viewer program (3DHISTECH Ltd., Budapest, Hungary).

Total RNA was extracted from lung homogenates using QIAamp Viral RNA (Qiagen ® ), according to manufacturer's instructions. Quantitative RT-PCR was performed using GoTaq ® 1-Step RT-qPCR System (Promega) in a StepOne ™ Real-Time PCR System (Thermo Fisher Scientific). Amplifications were carried out in 15 µL reaction mixtures containing 2× reaction mix buffer, 50 µM of each primer, 10 µM of the probe, and 5 µL of RNA template. Primers, probes, and cycling conditions recommended by the Centers for Disease Control and Prevention (CDC) protocol were used to detect the SARS-CoV-2 (CDC 2020). Amplification of the housekeeping gene HPRT1 (Mm03024075_m1, Thermo Fisher Scientific) was used as a reference for the number of cells used. The Ct values for this target were compared to those obtained with different cell quantities (10 7 to 10 2 ), for calibration.

African green monkey kidney cells (Vero, subtype E6) and the human lung epithelial cell lines (Calu-3) were expanded in high glucose DMEM with 100 U/mL penicillin and 100 mg/mL streptomycin (Pen/Strep; Gibco) and supplemented with 10% FBS. Cells were maintained at 37°C in a humidified atmosphere with 5% CO 2 .

PBMCs and neutrophils were isolated by density gradient centrifugation (Ficoll-Paque, GE Healthcare) from buffy-coat preparations of blood from healthy donors. Monocytes were isolated from PBMCs by plastic adherence. Briefly, PBMCs (2x10 6 cells) were plated onto 48-well plates (NalgeNunc) in RPMI-1640 with 5% inactivated male human AB serum (Merck) for 2 h. Non-adherent cells were washed out, and the remaining monocytes were maintained in DMEM (low glucose) with 5% human serum (Merck), 100 U/mL penicillin, and 100 mg/mL streptomycin (Pen/Strep; Gibco). The purity of human monocytes was higher than 90%, as determined by flow cytometric analysis (FACScan; Becton Dickinson) using anti-CD3 (BD Biosciences) and anti-CD14 (Southern Biotech) monoclonal antibodies. Neutrophils were isolated after two hypotonic lysis of erythrocytes, washed with PBS, and resuspended in RPMI.

Neutrophils (2x10 5 cells/well) were treated with simvastatin (10 mM) or medium for 30min at 37°C in RPMI, without serum. Then, cells were stimulated with PMA (100 nM) or inactivated SARS-CoV-2 (MOI 0.1) for 3 h, and the supernatants containing NETs were collected and centrifuged at 400 x g for 10 min to remove residual neutrophils. Quant-iT PicoGreen quantified the NETs. Neutrophils (2x10 5 /well) were treated with simvastatin (10 uM) or medium for 3 h at 37°C in RPMI, without serum. Next, cells were stimulated with PMA (100 nM), inactivated SARS-CoV-2 (MOI 0.1), and ROS production was evaluated using Dihydrorhodamine 123 (DHR) probe. (Excitation/ Emission: 500/570 nm, SpectraMax Paradigm reader).

For microscopy analysis, neutrophils (1x10 5 /well) were seeded in Labteks (Nalge Nunc) and treated with simvastatin (10uM) for 30 minutes. Next, cells were stimulated with inactivated SARS-CoV-2 (MOI 0.1) for 3 h at 37°C and fixed with 4% formaldehyde. NETs were stained with DAPI and visualized by fluorescence using ZEISS Axio Imager D2 microscope. Cytokines and chemokines were quantified in the supernatants containing NETs by ELISA using commercial kits (R&D Systems), following the datasheet instructions.

Cells were treated with simvastatin at indicated doses for 24 h before infection. Then, the medium was removed, and infections For viral titration, the plaque-forming assay was performed in monolayers of Vero E6 cells seeded in 96-well plates (2 x 10 4 cell/ well). Cell monolayers were infected with serial dilutions of the supernatants containing SARS-CoV-2 for 1 h at 37°C. The cells were overlaid with high glucose DMEM containing 2% FBS and 2.4% carboxymethylcellulose (CMC/DMEM high glucose semisolid medium). After 3 days, the cells were fixed with 10% formaldehyde, and the monolayers were stained with 0.04% crystal violet in 20% ethanol for 1 h. Viral titers were calculated by counting the plaques formed in at least three dilution replicates and expressed as plaque-forming unit per mL (PFU/mL).

Monolayers of Calu-3 cells (3x 10 5 cells/well in a 48-well plate) were treated with 25 µM simvastatin for 24 h. Thereafter, the medium was removed, and cells were exposed to SARS-CoV-2 at 0.1 MOI and incubated at 4°C for 1 h. For viral adsorption evaluation, following incubation time, cells were washed with cold PBS to remove the unabsorbed virus particles. Total RNA extraction and real-time PCR were performed as described above to measure the levels of viral adsorption. For internalization measurement, following incubation time, cells were washed with cold PBS and incubated at 37°C for 1 h. Then, cells were washed with PBS and treated with proteinase K (Invitrogen) for 45 min at 4°C to remove adsorbed but not internalized virus particles. After proteinase K inactivation with 2 mM PMSF in PBS-BSA, cells were pelleted in PBS containing 0.2% BSA. Following centrifugation of total RNA extraction, real-time PCR were performed as described above to measure the levels of viral internalization.

IL-6, TNF, IFN-a, CCL2/MCP1, CCL5/RANTES, CXCL1/KC, CXCL8/IL-8, CXL10/IP10 levels were quantified in cell-free culture supernatants from infected or uninfected cells and in pulmonary extracts from infected mice by ELISA, following the manufacturer's instructions (R&D Systems). Cell death was determined according to the activity of lactate dehydrogenase (LDH) in the culture supernatants and BAL using the CytoTox ® Kit (Promega, USA).

Cells were washed with ice-cold PBS and lysed in lysis buffer (1% Triton X-100, 2% SDS, 150 mM NaCl, 10 mM HEPES, 2 mM EDTA containing protease inhibitor cocktail (Roche, pH 8.0). After centrifugation at 13 000 g for 5 min, cell lysates were prepared in reducing and denaturing conditions and subjected to SDS-PAGE. Equal concentrations of proteins were fractionated by electrophoresis on 10% of acrylamide gels and were transferred onto a nitrocellulose membrane (Millipore, Billerica, MA, USA), followed by blocking of nonspecific binding sites in 5% nonfat milk in TBST (50 mM Tris-HCl -pH 7.4, 150 mM NaCl, 0.05% Tween 20) for 1 h at room temperature and blotted with primary antibodies in TBST overnight at 4°C. The following antibodies were used: anti-ACE2 (Proteintech-21115-1-AP), anti-TMPRSS2 (Proteintech-14437-1-AP), anti-GAPDH (Proteintech-60004-1-Ig), anti-CAV1 (Proteintech-16447-1-AP), and anti-FLOT1 (BD-610821). Proteins of interest were identified by incubating the membrane with IRDye ® LICOR or HRP-conjugated secondary antibodies in TBST, followed by detections by Supersignal Chemiluminescence (GE Healthcare) or by fluorescence imaging using the Odyssey system Odyssey ® (CLx Imaging System). Protein bands were quantified by densitometric image analysis using the ImageJ software.

Calu-3 cells seeded in 48-well plates (2 x 10 4 cell/well) with coverslips and the infections were performed with SARS-CoV-2 at MOI of 0.1 in high glucose DMEM without serum. After the infection, the viral inoculum was removed, cells were incubated with complete fresh medium containing (or not) simvastatin and maintained at 37°C for an additional 24 h. After 48h, the cells were fixed using 3.7% formaldehyde. Cells were rinsed three times with PBS containing 0.1 M CaCl2 and 1 M MgCl2 (PBS/ CM) and then permeabilized with 0.1% Triton X-100 plus 1% BSA in PBS/CM for 10 min (PBS/CM/TB). Cells were stained with rabbit monoclonal antibody anti-ACE2 (Proteintech-21115-1-AP) at 1:200 dilution for overnight, followed by a rabbit anti-IgG-Dylight 488 (Invitrogen-35502) at 1:500 dilution for 1h. The coverslips were mounted in slides using an antifade mounting medium (VECTASHIELD ® ). Nuclear recognition was based on DAPI staining (1 mg/mL) for 5 min. Fluorescence was analyzed by fluorescence microscopy with an 60x objective lens (Olympus, Tokyo, Japan).

Cells grown in 75 cm 2 flasks were washed three times with PBS saline buffer, scraped into 1.0 ml of lysis buffer [25 mM 2morpholino-ethanesulfonic acid (MES), pH 6.5, 150 mM NaCl, 1% (v/v) Triton X-100 containing protease and phosphatase inhibitor cocktail (Roche)], and lysed using a Dounce tissue grinder, after moving the tight pestle up and down five times. An equal volume of 90% (w/v) sucrose in MBS (25 mM MES, 150 Mm NaCl, pH 6.5) was added to cell homogenates. The samples were then transferred to a 6 mL ultracentrifuge tube and overlaid with discontinuous sucrose gradients consisting of 35% (w/v) sucrose in MBS (2 ml) and 5% (w/v) sucrose in MBS (2 ml). The sucrose gradients were centrifuged at 100,000 g for 18 h at 4°C in a Beckman MLS50 rotor, and fractions of 0.5 ml were harvested from the top to the bottom of the tube. All steps were carried out at 4°C. 

Statistics were performed using GraphPad Prism software version 8. Student's T-test was used to compare differences between two groups. One-way analysis of variance (ANOVA) was used to compare differences among 3 groups following a normal (parametric) distribution with Dunnett's post-hoc test was used to determine significant differences between groups; *p < 0.05; **p < 0.01; and ***p < 0.001.

K18-hACE2-transgenic mice mimic many of the clinical features of COVID-19, making it one of the best animal models currently available (19, 20) . As a proof-of-principle of the protective role of simvastatin for SARS-CoV-2 infection, K18-hACE2-transgenic mice were initially treated 24 h and 1 h before SARS-CoV-2 gamma strain infection with 20 mg/kg/day, a dose consistent with sepsis and malaria pre-clinical studies (17, 21) . After infection, these animals continued to receive the same dose daily throughout the experiment period. Viral load measurements performed on the sixth day post-infection revealed a lower number of viral genome copies ( Figure 1A ) in the lungs of animals in the simvastatin group alongside lower tissue damage inferred through LDH levels BAL ( Figure 1B) . At this point, the histological analysis of lung tissue demonstrated that SARS-CoV-2 infection-induced diffuse alveolar damage (DAD) with leukocyte infiltration, epithelial denudation, submucosal congestion, edema, and hemorrhage ( Figure 1C ). Despite simvastatin not completely reversed the DAD and edema in SARS-CoV-2 infected mice, the treatment led to an important decrease in tissue hemorrhage and inflammation. Simvastatin pretreatment confers resistance in the early stages of disease onset but does not alter its late outcome ( Figures 1D-F) . Simvastatin delayed the weight loss ( Figure 1D ) and other parameters of the disease measured by clinical score ( Figure 1E ). As a result of the delay in the pathophysiology of infection, we identified that simvastatin led to an increase in survival time compared to the vehicle group ( Figure 1F ). However, simvastatin treatment failed to inhibit mortality at later time points.

Overwhelming inflammation response is a pathological hallmark of COVID-19 disease, strongly associated with lung damage. Thus, we evaluated the effects of simvastatin on lung inflammation induced by SARS-CoV-2 infection. We observed that pretreatment with simvastatin failed to inhibit total leukocyte accumulation at the BAL on the sixth day of infection (Figure 2A) . Simvastatin-treated animals presented a significant reduction in the number of mononuclear leukocytes (Mono) and a predominance of polymorphonuclear leukocytes (PMN) (Figure 2A) . This phenomenon seems to be strongly associated with modifications of the main chemokines involved in leukocyte recruitment. We observed that simvastatin-treated group have an impaired the level of CCL2/MCP1 ( Figure 2C ) and CCL5/RANTES ( Figure 2D) , but not of level CXCL1/KC ( Figure 2E ) induced by SARS-CoV-2 infection. Of note, although simvastatin failed to inhibit neutrophil recruitment to the BAL, we observed a significant reduction in myeloperoxidase (MPO) detected in the lungs of simvastatin treated animals indicative of decreased accumulation of neutrophils in the lungs ( Figure 2B ). The pretreatment with simvastatin also significantly reduced the level of IL-6, but not TNF levels ( Figures 2F-G) , induced by SARS-CoV-2 infection in the lung tissue. Together, these data suggest that anti-inflammatory effects of simvastatin are also important components in reducing the pulmonary damage induced by SARS-CoV-2 infection.

Activated neutrophils play central role in inflammatory response during COVID-19 but also contribute to lung damage through the process of degranulation and NETosis (22, 23) . Thus, our next step was to assess the effects of simvastatin on neutrophils in vitro. Neutrophils exposed to inactivated SARS-CoV-2 virions increase NET formation ( Figures 3A, B) . Simvastatin pretreatment did not prevent NETosis induced by inactivated SARS-CoV-2 virions or PMA, a well-characterized agonist for NET formation ( Figure 3B ) However, simvastatin significantly reduced the oxidative stress measured by oxidation of DHR probe ( Figure 3C ) and the levels of inflammatory mediators TNF ( Figure 3D ), CCL5/RANTES ( Figure 3E ) and CXCL10/IP-10 ( Figure 3F ) induced by SARS-CoV-2 or PMA treatment.

Next, we evaluated the ability of simvastatin to modulate the inflammatory response in SARS-CoV-2-infected monocytes, cells critically involved in COVID-19 pulmonary inflammation, using two treatment strategies, as shown in Figure 4A . First, we evaluated the simvastatin effect on pre-treated monocytes (treatment remains after infection period) and its therapeutic potential by post-treating these cells ( Figure 4A ). We found that either schedule of simvastatin treatment decreased the production of TNF, CXCL-8/IL-8, IL-6, and IFN-a ( Figures 4B-E) induced by SARS-CoV-2 infection in human monocytes. Of note, both treatment strategies did not alter the levels of IL-1b, CCL2/MCP-1, CXCL10/IP-10, and IL-10 induced by SARS-CoV-2 infection (data not shown). Since SARS-CoV-2 infection is reported to induce monocyte death by pyroptosis (24), we also evaluated whether simvastatin treatment could reverse this phenomenon by measuring cytoplasmic LDH leak in culture supernatants. We observed that both pretreatment and posttreatment only with 10 µM of simvastatin prevented monocyte death induced by SARS-CoV-2 infection ( Figure 4F ). 3 cells (Figures 5D-F) . Taken together, these data strengthen the protective role of simvastatin against SARS-CoV-2 infection and suggest that simvastatin effects occur at the early stages of infection.

Simvastatin's capacity to lower cholesterol synthesis may alter plasma membrane composition, which is critical for viral infection. Based on this property, we evaluated the effect of simvastatin pre and posttreatment on SARS-CoV-2 infection in permissive cells. We observed that pretreatment with simvastatin reduced the viral load in Calu-3 cells in a dose-dependent manner, with an IC50 of 13.9 µM ( Figure 6A) . Along with the impairment of virus replication, simvastatin attenuated SARS-CoV-2-induced cell death as measured by LDH release ( Figure 6C ). On the other hand, the posttreatment with simvastatin failed to inhibit SARS-CoV-2 replication (Figures 6B, D) . The same phenomenon was also observed in Vero E6 cells, a cell lineage highly permissive to SARS-CoV-2 infection. We observed that only pretreatment of Vero E6 cells with simvastatin reduced the infectivity of SARS-CoV-2 in a dose-dependent way ( Figure S1 ).

To further gain insight on the mechanism by which simvastatin impairs SARS-CoV-2 infection, we investigated whether this compound affects SARS-CoV-2 adsorption and internalization. Our data show that simvastatin significantly inhibits virus adsorption ( Figure 7A ) and virus entry ( Figure 7B ), which could contribute to further reduced virus production. To understand the mechanism of action of simvastatin on SARS-CoV-2 attachment and entry, we evaluated the level of expression of ACE2 and TMPRSS2, which SARS-CoV-2 explores for cell entry. Surprisingly, ACE2 expression was enhanced after 24 h and 48 h of simvastatin treatment ( Figure 7C ). Despite the enhancement of ACE2 expression by simvastatin pretreatment, SARS-CoV-2 binds to the cell surface less efficiently ( Figure 7A ) and virus internalization is reduced ( Figure 7B) . We also detected an increase of ACE2 expression level in Vero E6 cells after 24 h treatment with simvastatin and a further increase after SARS-CoV-2 infection compared to cells infected but not treated with simvastatin ( Figure S2 ). On the other hand, the expression levels of TMPRSS2, the cellular serine protease that primes SARS-CoV-2 Spike protein for entry (25) , remained unchanged in all conditions analyzed in both cell types ( Figure 7C and Supplementary Figure S2) . These findings suggest that, although simvastatin treatment increases the global expression of ACE2 in the cell, it somehow prevents the correct interaction of the viral spike protein with its receptor, probably due to the well-known effect of simvastatin in disrupting lipid rafts.

To advance the understanding of the mechanisms by which simvastatin pretreatment impairs adsorption and internalization of SARS-CoV-2, we decided to study the impacts of this treatment also in the subcellular location of ACE2 ( Figure 7D ). In mock condition, ACE2 is localized primarily at the cell surface as expected for this cell line. The pretreatment with simvastatin induces a subcellular redistribution of ACE2.

The intense concentration of receptors on the plasma membrane were no longer visible and green signals were instead seen as a diffuse labeling. Since statins directly interfere with the integrity of cholesterol microdomains in the plasma membrane, the receptors are likely to have diffused across the lipid bilayer and/or been internalized. To confirm whether the effect of simvastatin in SARS-CoV-2 is related to rafts disturbance, we also evaluated the location of ACE2 and TMPRSS2 in lipid rafts by protein solubilization in cold Triton X-100 buffer, followed by cell fractionation in discontinuous sucrose gradient. In control cells, a substantial amount of ACE2 co-fractionates with the raft marker caveolin-1 (Cav-1) and flotillin-1 (FLOT1) in fractions 4-6 ( Figure 7E ). In contrast, TMPRSS2 was confined to the detergent-soluble fractions 7-11. Treatment with simvastatin promoted the movement of ACE2 to the detergent-soluble fractions, while the localization of TMPRSS2 in the cellular membrane remained unchanged. Altogether, our data suggest that simvastatin inhibits SARS-CoV-2 binding and entry to the cell by disrupting the lipid environment of the plasma membrane raft structure, altering the location of ACE2, and thus, impeding the proper interaction with the virus.

Statins combine antiinflammatory, antithrombotic, and immunomodulatory effects that potentially meet the main demands of those affected by COVID-19 (12, 26) . Several retrospective observational clinical studies have recently attested to the beneficial effects of previous and prolonged use of statins and their in-hospital introduction after SARS-CoV-2 infection on patients' prognosis (7, 15, 27, 28) . However, experimental evidence showing how the use of statins can affect the course of SARS-CoV-2 infection is scarce. We demonstrated that simvastatin reduced viral replication and production of inflammatory mediators induced by SARS-CoV-2 in vivo and in vitro infected cells. In addition, simvastatin delayed the weight loss and mortality induced by SARS-CoV-2 in ACE2 transgenic mice. However, simvastatin treatment failed to inhibit mortality at later time points. As a sepsis-like phenomenon, the systemic cytokine storm contributes to airways and extrapulmonary organ damage (29) . Our results suggest that the regulation of the inflammatory response triggered by SARS-CoV-2 in COVID-19 patients may be an important component in the resistance conferred to statin users as well as those who received statins in-hospital. In this sense, the antiinflammatory effect of statins is a wellcharacterized phenomenon in several infection models (10, 11, 30, 31) . Moreover, statins downregulate pro-inflammatory response by inhibiting both NF-kB-mediated cytokine induction and NLRP3 inflammasome activation (13), essential components for the hyperinflammatory response triggered by SARS-CoV-2 infection (24, 25, 32) . This antiinflammatory effect of statins may explain the delayed pathophysiology of COVID-19 and mortality, and lower recruitment of monocytes to the lung. Moreover, monocytic cells are a major cellular component of the pulmonary cell infiltrate, and macrophage activation syndrome (MAS)-like accounts for several features of COVID-19 pathogenesis (33) . On the other hand, NETs released by Similarly, in peripheral blood monocytes, 24h pretreatment was more effective when compared to posttreatment only. SARS-CoV-2 interacts with receptors embedded in the plasma membrane in specifically organized microdomains known as lipid rafts (34) . Lipid rafts are cholesterol-and sphingolipids-enriched plasma membrane regions that have reduced fluidity and selectively incorporate or exclude proteins (35) (36) (37) . Thus, lipid rafts can compartmentalize specific components and mediate important cell events as a signaling platform (38) . Numerous enveloped viruses, including members of the Coronaviridae family (37), exploit lipid rafts in distinct steps of their life cycle, such as cell entry, trafficking, signaling, and budding of the cell (39) . Data from our adsorption assay confirmed that treatment with simvastatin impairs virus-cell tethering and reduces the number of viral particles that reach the intracellular compartment. This result agrees that simvastatin disrupts the composition and properties of lipid rafts (37) , which was proven to be essential for the interaction of SARS-CoV spike protein. Accordingly, recently it has been shown that the depletion of cholesterol in the plasma membrane and its abnormal redistribution into intracellular compartments slows down the kinetic of SARS-CoV-2 infection by suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication (40, 41) . Moreover, other raft-resident lipids such as sphingolipids and ceramides were seen as important in the mechanisms of fusion and virus entry into the cell, highlighting the importance of the integrity of lipid rafts in these mechanisms (42) . In this context, the pharmacological redistribution of cholesterol and impaired lipid raft formation hampers the SARS-CoV-2 SARS-CoV-2 entry, and consequently the virus replication (34, (43) (44) (45) . In line with the results obtained here with simvastatin pretreatment, other drugs that affect not only the synthesis but also the traffic of cholesterol through the endosomal pathway, such as itraconazole, fluoxetine and amitriptyline showed promising results as adjuvant therapy for COVID-19 (42, 46, 47) . Interestingly, as reported by our study and others (48) (49) (50) (51) (52) , statins can increase the expression of ACE2, the central receptor for recognition and entry of SARS-CoV-2 into the host cell (53, 54) . However, subcellular fractionation revealed that the ACE2 receptor is misplaced after simvastatin treatment, being reduced in lipid rafts despite its global enhancement. Therefore, these results suggest that simvastatin impairs the early stages of SARS-CoV-2 infection by disrupting lipid rafts and preventing the proper interaction of viral particles with ACE2 receptors. Similar results were obtained by depletion of plasma membrane cholesterol with methyl-b-cyclodextrin (MbCD), which disrupts lipid rafts and relocates ACE2 to a non-raft environment impacting SARS-CoV infectivity (55) . ACE2 is a master regulator of the renin-angiotensin system (56) and has shown to be protective during SARS-CoV-2 infection by downregulating Ang II-mediated vascular permeability and acute lung injury (57, 58) . The activity of ACE2 provokes a shift from Ang II toward Ag-(1-7) availability, which has been shown to reduce systemic inflammation in a phase-2 clinical trial of recombinant ACE2 (59) . Thus, the elevated levels of ACE2 induced by simvastatin are not necessarily detrimental during SARS-CoV-2 infection.

In this work, we investigated whether simvastatin would have protective effects against COVID-19 in vivo and in vitro and shed light on mechanisms of action. However, it is crucial to highlight some limitations of this study. The dose of simvastatin used in mouse experiments was based on numerous studies that use between 10-40 mg/kg to evaluate the effects of simvastatin in different infection and sterile models of disease (17, 21, 49, (60) (61) (62) . However, it is important to note that these doses are higher than that routinely applied in human clinical use, limited to a maximum of 80 mg per day (63, 64) . As such, the doses used in this article in mice cannot be extrapolated to humans and future randomized clinical studies would be necessary to confirm the potential beneficial effects to humans. Nevertheless, our results suggest that simvastatin treatment may have adjuvant beneficial therapeutic effect on COVID-19 as for patients who already have been using the statins chronically.

In summary, our data showed that simvastatin is endowed with the ability to reduce the inflammatory response associated with SARS-CoV-2 infection both in vivo and in vitro (Figure 8 ).

Our results suggest that simvastatin-induced modifications in cellular components are essential to decrease the inflammatory response related to COVID-19. Moreover, our data demonstrate that simvastatin disrupts lipid rafts relocating ACE2 to the nonraft membrane, which possibly hampers interaction of ACE2 and SARS-CoV-2, preventing infection ( Figure 8) . Thus, our data 

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

The studies involving human participants were reviewed and approved by 

A Novel Coronavirus From Patients With Pneumonia in China

Extrapulmonary Manifestations of COVID-19

SARS-CoV-2 and Viral Sepsis: Observations and Hypotheses

Potential Effects of Coronaviruses on the Cardiovascular System

Factors Associated With COVID-19-Related Death Using OpenSAFELY

Relation of Statin Use Prior to Admission to Severity and Recovery Among

Statin Use is Associated With Lower Disease Severity in COVID-19

Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?

Signaling and Sorting Platforms of Cells and Their Roles in Cancer

Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms

Immune Modulatory Effects of Statins

Teaching Old Drugs New Tricks: Statins for COVID-19?

Statins: Could an Old Friend Help in the Fight Against COVID-19?

Statin Therapy in COVID-19 Infection

EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED

Statins Reduce Mortality in Patients With COVID-19: An Updated Meta-Analysis of 147 824 Patients

Statins Prevent Cognitive Impairment After Sepsis by Reverting Neuroinflammation, and Microcirculatory/Endothelial Dysfunction

Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content With an Enzyme Marker

K18-Hace2 Mice Develop Respiratory Disease Resembling Severe COVID-19

SARS-CoV-2 Infection of Human ACE2-Transgenic Mice Causes Severe Lung Inflammation and Impaired Function

Statins Decrease Neuroinflammation and Prevent Cognitive Impairment After Cerebral Malaria

Monocyte-Driven Atypical Cytokine Storm and Aberrant Neutrophil Activation as Key Mediators of COVID-19 Disease Severity

SARS-CoV-2-Triggered Neutrophil Extracellular Traps Mediate

SARS-CoV-2 Engages Inflammasome and Pyroptosis in Human Primary Monocytes

COVID-19: A New Virus, But a Familiar Receptor and Cytokine Release Syndrome

Potential Role of Statins in COVID-19

Simvastatin Downregulates SARS-CoV-2 Infection

Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study

In-Hospital Use of Statins Is Associated With a Reduced Risk of Mortality Among Individuals With COVID-19

The Trinity of COVID-19: Immunity, Inflammation and Intervention

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Decrease Fas Ligand Expression and Cytotoxicity in Activated Human T Lymphocytes

Potential Therapeutic Role for Statins in Respiratory Disease

Inflammasomes are Activated in Response to SARS-CoV-2 Infection and are Associated With COVID-19 Severity in Patients

Immune Mechanisms of Pulmonary Intravascular Coagulopathy

Dependence of SARS-CoV-2 Infection on Cholesterol-Rich Lipid Raft and Endosomal Acidification

Structure and Function of Sphingolipid-and Cholesterol-Rich Membrane Rafts

The Mystery of Membrane Organization: Composition, Regulation and Roles of Lipid Rafts

Targeting Lipid Rafts as a Strategy Against Coronavirus

Lipid Rafts and Signal Transduction

Pathogens: Raft Hijackers

Cholesterol 25-Hydroxylase Inhibits SARS-CoV-2 and Other Coronaviruses by Depleting Membrane Cholesterol

Cholesterol 25-Hydroxylase Suppresses SARS-CoV-2 Replication by Blocking Membrane Fusion

Sphingolipids as Modulators of SARS-CoV-2 Infection

Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry

Targeting the Endolysosomal Host-SARS-CoV-2 Interface by Clinically Licensed Functional Inhibitors of Acid Sphingomyelinase (FIASMA) Including the Antidepressant Fluoxetine

The Role of High Cholesterol in Age Related COVID19 Lethality. bioRxiv

Drug Synergy of Combinatory Treatment With Remdesivir and the Repurposed Drugs Fluoxetine and Itraconazole Effectively Impairs SARS-CoV-2 Infection In Vitro

In Vitro Activity of Itraconazole Against SARS-CoV-2

Overexpression of ACE2 Enhances Plaque Stability in a Rabbit Model of Atherosclerosis

Effects of Pravastatin on Type 1 Diabetic Rat Heart With or Without Blood Glycemic Control

The Effect of Fluvastatin on Cardiac Fibrosis and Angiotensin-Converting Enzyme-2 Expression in Glucose-Controlled Diabetic Rat Hearts

Tissue Specific Up Regulation of ACE2 in Rabbit Model of Atherosclerosis by Atorvastatin: Role of Epigenetic Histone Modifications

Effects of Rosuvastatin on Expression of Angiotensin-Converting Enzyme 2 After Vascular Balloon Injury in Rats

Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Lipid Rafts are Involved in SARS-CoV Entry Into Vero E6 Cells

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Angiotensin-Converting Enzyme 2 Protects From Severe Acute Lung Failure

A Crucial Role of Angiotensin Converting Enzyme 2 (ACE2) in SARS Coronavirus-Induced Lung Injury

A Potential Therapeutic Role for Angiotensin-Converting Enzyme 2 in Human Pulmonary Arterial Hypertension

A Functional Cerebral Endothelium is Necessary to Protect Against Cognitive Decline

Simvastatin Protects Against the Development of Endometriosis in a Nude Mouse Model

Impact of Oral Simvastatin Therapy on Acute Lung Injury in Mice During Pneumococcal Pneumonia

Intensive Lowering of LDL Cholesterol With 80 Mg Versus 20 Mg Simvastatin Daily in 12 064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial

Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs

The authors are grateful to the Hemotherapy Service of the Hospital Clementino Fraga Filho (Federal University of Rio de Janeiro, Brazil) for providing buffy coats. We thank to Fiocruz Luminex Platform (Subunidade Luminex-RPT03C Rede de Plataformas PDTIS, FIOCRUZ/RJ) and the assistance of MSc Edson Fernandes de Assis for the use of its Luminex facilities. The authors also acknowledge Patricia Machado Rodrigues e Silva Martins and Tatiana Paula Teixeira Ferreira from Fiocruz for the microphotographs analysis.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.